Pharmacodynamics of XXXX -induced @entity4053 in @entity35 .

@entity2050 @entity5354 @entity4053 @entity35 @entity413
@entity4053 is one of the serious adverse effects induced by @entity5354 ( @entity2050 ), an antiarrhythmic agent. In order to clarify the pharmacodynamics of @entity2050 -induced @entity4053 , @entity2050 was administered intravenously to conscious @entity35 at a dose of 5, 10 or 20 mg/kg and serum samples were collected periodically to determine the concentrations of @entity2050 , insulin and @entity413 . The pharmacokinetics of @entity2050 showed nonlinear characteristics and could be described by a two-compartment model with Michaelis-Menten elimination kinetics. @entity2050 induced a rapid increase in the serum concentration of insulin. As the @entity2050 dose was increased, a greater hypoglycemic effect occurred. The indirect response model was applied to account for the @entity2050 -induced increase in insulin secretion and the subsequent decrease in serum @entity413 . A linear relationship was assumed between the serum concentration of @entity2050 and its stimulating effect on insulin secretion. A nonlinear relationship was assumed between the serum concentration of insulin and its stimulating effect on the elimination of serum @entity413 . The time courses of serum concentrations of @entity2050 , insulin and @entity413 after intravenous injection of @entity2050 could be described by the pharmacokinetic and pharmacodynamic model developed. This approach will be useful for the identification of variable factors related to @entity2050 -induced @entity4053 .
